PHI with Werdnig-Hoffmann disease
How does this condition affect your private health insurance?
Werdnig-Hoffmann disease, also known as Spinal Muscular Atrophy Type 1 (SMA Type 1), is a severe, autosomal recessive neuromuscular disorder characterized by the progressive degeneration of anterior horn cells in the spinal cord, leading to profound muscle weakness and atrophy. Symptoms typically manifest at birth or within the first six months, including severe hypotonia, absent deep tendon reflexes, and difficulty feeding and breathing. The disease rapidly progresses, causing respiratory failure due to diaphragm and intercostal muscle weakness. Without intervention, affected infants rarely survive beyond two years of age. Current treatments aim to slow progression and manage symptoms.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Symptoms appear at birth or within the first 6 months, with rapid progression.
Duration of Illness (Lifetime)
A progressive, life-limiting condition, typically fatal in early childhood without extensive medical intervention.
Cost of Treatment (Initial)
High (initial diagnosis, hospitalization, and supportive care can be substantial).
Cost of Treatment (Lifetime)
Extremely high (includes ongoing intensive supportive care, respiratory assistance, feeding support, physical therapy, and potentially very expensive gene or disease-modifying therapies).
Mortality Rate
Very high (historically, over 90% by age 2 without treatment; still high even with modern interventions).
Risk of Secondary Damages
Very high (includes severe respiratory insufficiency, recurrent infections, feeding difficulties, aspiration pneumonia, joint contractures, and severe scoliosis).
Probability of Full Recovery
Negligible (currently no cure; treatments aim to slow progression and manage symptoms).
Underlying Disease Risk
This is a primary genetic disease; however, patients are at very high risk for severe secondary complications such as recurrent respiratory infections and failure to thrive due to progressive muscle weakness.